Recently, Ruiyi Xulian made the announcement that it has successfully secured nearly 100 million yuan in Pre-A round funding. This funding round was spearheaded by Nuoyu Capital and Wellead Medical, with several other institutions joining in and existing shareholders continuing their support. The capital raised will be channeled towards bolstering the research, development, and deployment of full-stack technology for implantable bidirectional brain-computer interfaces. It will also expedite the large-scale production and clinical implementation of the "Brain-Spinal Cord Interface," delve into diverse application scenarios, and foster the commercialization of products already available in the market. Established in 2024, Ruiyi Xulian has set its sights on addressing major brain diseases and is wholeheartedly committed to the research, development, and clinical utilization of implantable brain-computer interfaces. Presently, the company has successfully developed a prototype of a fully implantable brain-computer interface and carried out comprehensive animal experiments involving fully implantable devices. It is on the verge of launching animal experiments using non-human primate models and anticipates obtaining a Class III medical device registration certificate by 2028. Moreover, the "Brain-Spinal Cord Interface" has commenced mass production, and the "NeuroPulse Portable Four-Channel Electrical Stimulation Therapy Device" is already available for purchase in the market. The company is also vigorously pursuing the development of wearable consumer and brain-computer interface products.